Pérez JM - Search Results

1

Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.

Nguewa PA, Fuertes MA, Valladares B, Alonso C, Pérez JM. Nguewa PA, et al. Among authors: perez jm. Prog Biophys Mol Biol. 2005 May;88(1):143-72. doi: 10.1016/j.pbiomolbio.2004.01.001. Prog Biophys Mol Biol. 2005. PMID: 15561303 Free article. Review.

2

Is cisplatin-induced cell death always produced by apoptosis?

Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Gonzalez VM, et al. Among authors: perez jm. Mol Pharmacol. 2001 Apr;59(4):657-63. doi: 10.1124/mol.59.4.657. Mol Pharmacol. 2001. PMID: 11259608 Review.

3

Pharmacological modulation of Poly(ADP-ribose) polymerase-mediated cell death: exploitation in cancer chemotherapy.

Nguewa PA, Fuertes MA, Alonso C, Perez JM. Nguewa PA, et al. Among authors: perez jm. Mol Pharmacol. 2003 Nov;64(5):1007-14. doi: 10.1124/mol.64.5.1007. Mol Pharmacol. 2003. PMID: 14573748 Review. No abstract available.

4

Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells.

Nguewa PA, Fuertes MA, Cepeda V, Alonso C, Quevedo C, Soto M, Pérez JM. Nguewa PA, et al. Among authors: perez jm. Med Chem. 2006 Jan;2(1):47-53. doi: 10.2174/157340606775197697. Med Chem. 2006. PMID: 16787355

5

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.

Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Soto M, Pérez JM. Cepeda V, et al. Among authors: perez jm. Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):39-53. doi: 10.2174/157489206775246430. Recent Pat Anticancer Drug Discov. 2006. PMID: 18221025 Review.

6

The formation of DNA interstrand cross-links by a novel bis-[Pt2Cl4(diminazene aceturate)2]Cl4.4H2O complex inhibits the B to Z transition.

González VM, Fuertes MA, Jiménez-Ruíz A, Alonso C, Pérez JM. González VM, et al. Among authors: perez jm. Mol Pharmacol. 1999 Apr;55(4):770-7. Mol Pharmacol. 1999. PMID: 10101036

7

Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways.

Fuertes MA, Castilla J, Alonso C, Pérez JM. Fuertes MA, et al. Among authors: perez jm. Curr Med Chem. 2003 Feb;10(3):257-66. doi: 10.2174/0929867033368484. Curr Med Chem. 2003. PMID: 12570712 Review.

8

Novel concepts in the development of platinum antitumor drugs.

Fuertes MA, Castilla J, Alonso C, Pérez JM. Fuertes MA, et al. Among authors: perez jm. Curr Med Chem Anticancer Agents. 2002 Jul;2(4):539-51. doi: 10.2174/1568011023353958. Curr Med Chem Anticancer Agents. 2002. PMID: 12678734 Review.

9

Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)].

Pérez JM, Kelland LR, Montero EI, Boxall FE, Fuertes MA, Alonso C, Navarro-Ranninger C. Pérez JM, et al. Mol Pharmacol. 2003 Apr;63(4):933-44. doi: 10.1124/mol.63.4.933. Mol Pharmacol. 2003. PMID: 12644595

10

Programmed cell death in trypanosomatids: a way to maximize their biological fitness?

Nguewa PA, Fuertes MA, Valladares B, Alonso C, Pérez JM. Nguewa PA, et al. Among authors: perez jm. Trends Parasitol. 2004 Aug;20(8):375-80. doi: 10.1016/j.pt.2004.05.006. Trends Parasitol. 2004. PMID: 15246321 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

540 results

Search Page